Mutant vesicular stomatitis viruses and uses thereof
AssigneesOttawa Hospital Research Institute, Wellstat Biologics Corporation
InventorsJohn C. Bell, Brian D. Lichty, David F. Stojdl
Life of this patent
Estimating the term…
Abstract
The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.
Claims17
A mutant vesicular stomatitis virus (VSV) having the mutation ΔM51 in the gene encoding the matrix (M) protein.
A vaccine vector comprising a mutant VSV having the mutation ΔM51 in the matrix (M) protein and a heterologous nucleic acid encoding one or more antigens.
A vaccine adjuvant comprising a mutant VSV having the mutation ΔM51 in the matrix (M) protein, said mutant VSV being capable of triggering the production of one or more cytokines in an infected cell.
A selective oncolytic agent comprising a mutant VSV having the mutation ΔM51 in the matrix (M) protein.
A pharmaceutical composition comprising a mutant VSV having the mutation ΔM51 in the matrix (M) protein.
An immunogenic composition comprising a mutant VSV having the mutation ΔM51 in the matrix (M) protein and a pharmaceutically acceptable carrier, said mutant VSV being capable of triggering the production of one or more cytokines in an infected cell.
A kit comprising one or more containers and a mutant VSV having the mutation ΔM51 in the gene encoding the matrix (M) protein.
Dependencies are inferred from the claim text.